These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31941683)

  • 1. Selected Articles from This Issue.
    Clin Cancer Res; 2020 Jan; 26(2):323. PubMed ID: 31941683
    [No Abstract]   [Full Text] [Related]  

  • 2. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
    Atanackovic D; Yousef S; Shorter C; Tantravahi SK; Steinbach M; Iglesias F; Sborov D; Radhakrishnan SV; Chiron M; Miles R; Salama M; Kröger N; Luetkens T
    Leukemia; 2020 Jan; 34(1):317-321. PubMed ID: 31409922
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.
    von Tresckow B; Boell B; Eichenauer D; Beschorner D; Knop S; Goebeler ME; Chemnitz JM; Hallek M; Engert A; Huebel K
    Leuk Lymphoma; 2014 Mar; 55(3):695-7. PubMed ID: 23713484
    [No Abstract]   [Full Text] [Related]  

  • 5. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three new drugs for multiple myeloma.
    Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immuno-oncology. A promising way to fight cancer].
    Sabourin G
    Perspect Infirm; 2015; 12(3):60. PubMed ID: 26079038
    [No Abstract]   [Full Text] [Related]  

  • 8. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 11. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 12. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
    Kuroda J; Nagoshi H; Shimura Y; Taniwaki M
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
    Lonial S
    Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Resistant mechanisms against breast cancer treatment and therapeutic strategies].
    Tanizaki J; Tsurutani J
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():336-40. PubMed ID: 23513862
    [No Abstract]   [Full Text] [Related]  

  • 15. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VIII. Novel Drugs for Multiple Myeloma].
    Shibayama H
    Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1255-60. PubMed ID: 30168970
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
    Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
    Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elotuzumab for the treatment of multiple myeloma.
    Wang Y; Sanchez L; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary malignant neoplasms and cytostatic therapy].
    Gerhartz D
    Lebensversicher Med; 1982 Jun; 34(5):110-3. PubMed ID: 6125858
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.